Top

Published in:

01-12-2013 | Gynecologic Oncology

Polymorphism and overexpression of HER2/neu among ovarian carcinoma women from Tiruchirapalli, Tamil Nadu, India

Authors: Santhanam Shanmughapriya, G. Senthilkumar, Seshachalam Arun, Krishnakumar Vinodhini, Sivasubramanian Sudhakar, Kalimuthusamy Natarajaseenivasan

Published in: Archives of Gynecology and Obstetrics | Issue 6/2013

Abstract

Purpose

Alteration and overexpression of HER2 proto-oncogene have been implicated in the carcinogenesis and prognosis of ovarian cancer. We evaluated this hypothesis among women with ovarian carcinoma patients from Tiruchirapalli, Tamil Nadu, India.

Methods

Genomic DNA was extracted from 72 case patients and 288 control subjects and was examined for I655V polymorphism by PCR–RFLP based assay. Immunohistochemistry analysis was carried out in order to study the overexpression of HER2 protein. The observed number of each genotype was compared with that expected for a population in the Hardy–Weinberg equilibrium. In analysing the relation between genotype and overexpression of HER2 protein, Cochran-Mantel–Haenszel statistics was used.

Results

We found that 20.8 % of the case patients and 16.3 % of the control subjects were heterozygous for the Val allele and 10 case patients (13.8 %) and 3 control subjects (1.1 %) were homozygous for this allele (P < 0.001). Compared with women with Ile/Ile genotype, women with Val/Val genotype had an elevated risk of ovarian cancer. The genotype distributions were consistent with the Hardy–Weinberg equilibrium. The risk increased with the number of Val allele and women homozygous for the Val allele had 15-fold (OR = 15.3; 95 %CI = 4.09–57.31) increased risk of cancer. The patients homozygous for the Valine allele showed strong HER2 protein expression.

Conclusion

The results showed that the valine allele may be an indicator of genetic susceptibility to ovarian carcinoma in the study population.

Gadducci A, Cosio S, Gargini A et al (2004) Sex-steroid hormones, gonadotropin and ovarian carcinogenesis: a review of epidemiological and experimental data. Gynecol Endocrinol 19:216–228PubMedCrossRef

Tingulstad S, Skjeldestad FE, Halvorsen TB et al (2003) Survival and prognostic factors in patients with ovarian cancer. Obstet Gynecol 101:885–891PubMedCrossRef

Parazzini F, Franceschi S, La Vecchia C et al (1990) Review: the epidemiology of ovarian cancer. Gynecol Oncol 43:9–23CrossRef

National Cancer Registry Program (2010) Three year report of population based cancer registries (2006–2008), Bangalore, India

Roses AD (2004) Pharmacogenetics and drug development: the path to safer and more effective drugs. Nat Rev Genet 5:645–656PubMedCrossRef

Medeiros R, Pereira D, Afonso N et al (2003) Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome. Int J Clin Oncol 8:156–161PubMedCrossRef

Roskoski R (2004) The ErbB/HER receptor protein-tyrosine kinases and cancer. Biochem Biophys Res Commun 319:1–11PubMedCrossRef

Akiyama T, Sudo C, Ogawara H et al (1986) The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 232:1644–1646PubMedCrossRef

Graus-Porta D, Beerli RR, Daly JM et al (1997) ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signalling. Eur Med Biol Org J 16:1647–1655

10.

Sliwkowsk MX, Schaefer G, Akita RW et al (1994) Coexpression of erbB-2 and erbB-3 proteins reconstitutes a high affinity receptor for heregulin. J Biol Chem 269:14661–14665

11.

Di Fiore PP, Pierce JH, Kraus MH et al (1987) erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237:178–182PubMedCrossRef

12.

Stern DF, Kamps MP, Cao H (1988) Oncogene activation of p185neu stimulates tyrosine phosphorylation in vivo. Mol Cell Biol 8:3969–3973PubMed

13.

Papewalis J, Nikitin AY, Rajewsky MF (1991) G to A polymorphism at amino acid codon 655 of the human erbB-2/HER2 gene. Nucleic Acids Res 19:5452PubMedCrossRef

14.

Hishida A, Hamajima N, Iwata H et al (2002) Re: population-based, case–control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 94:1807–1808PubMedCrossRef

15.

Xie D, Shu XO, Deng Z et al (2000) Population-based, case–control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 92:412–417PubMedCrossRef

16.

Mullenbach R, Lagoda PJ, Welter C (1989) An efficient salt–chloroform extraction of DNA from blood and tissues. Trends Genet 5:391PubMed

17.

Pinto D, Pereira D, Portela C et al (2005) The influence of HER2 genotypes as molecular markers in ovarian cancer outcome. Biochem Biophys Res Commun 335:1173–1178PubMedCrossRef

18.

Spitz MR, Wu X, Mills G (2005) Integrative epidemiology: from risk assessment to outcome prediction. J Clin Oncol 23:267–275PubMedCrossRef

19.

Bargmann CI, Hung MC, Weinberg RA (1986) Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 45:649–657PubMedCrossRef

20.

Guy CT, Webster MA, Schaller M et al (1992) Expression of the neu proto-oncogene in the mammary epithelium of transgenic mice induces metastatic disease. PNAS 89:10578–10582PubMedCrossRef

21.

Keshava C, McCanlies EC, Keshava N et al (2001) Distribution of HER2(V655) genotypes in breast cancer cases and controls in the United States. Cancer Lett 173:37–41PubMedCrossRef

22.

Millikan R, Eaton A, Worley K et al (2003) HER2 codon 655 polymorphism and risk of breast cancer in African American and whites. Breast Cancer Res Treat 79:355–364PubMedCrossRef

23.

Ameyaw MM, Thornton N, McLeod HL (2000) Re: population based, case–control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 92:1947PubMedCrossRef

24.

Akisik E, Dalay N (2004) Estrogen receptor codon 594 and HER2 codon 655 polymorphisms and breast cancer risk. Exp Mol Pathol 76:260–263PubMedCrossRef

25.

Fasching PA, Gayther S, Pearce L (2009) Role of genetic polymorphisms and ovarian cancer susceptibility. Mol oncol 3:171–181PubMedCrossRef

26.

Fleishman SJ, Schlessinger J, Ben-Tal N (2002) A putative molecular activation switch in the transmembrane domain of erbB2. PNAS 99:15937–15940PubMedCrossRef

Title: Polymorphism and overexpression of HER2/neu among ovarian carcinoma women from Tiruchirapalli, Tamil Nadu, India
Authors: Santhanam Shanmughapriya
G. Senthilkumar
Seshachalam Arun
Krishnakumar Vinodhini
Sivasubramanian Sudhakar
Kalimuthusamy Natarajaseenivasan
Publication date: 01-12-2013
Publisher: Springer Berlin Heidelberg
Published in: Archives of Gynecology and Obstetrics / Issue 6/2013
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI: https://doi.org/10.1007/s00404-013-2892-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Polymorphism and overexpression of HER2/neu among ovarian carcinoma women from Tiruchirapalli, Tamil Nadu, India

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2013

Comparison of administration of single dose ceftriaxone for elective caesarean section before skin incision and after cord clamping in preventing post-operative infectious morbidity

Indocyanine green fluorescence imaging in the pregnant cynomolgus macaque: childbearing is supported by a unilateral uterine artery and vein alone?

Maternal serum leptin as a marker of preeclampsia

Magnesium supplementation to prevent high blood pressure in pregnancy: a randomised placebo control trial

Severe retroperitoneal haemorrhage in the first trimester of a multiple pregnancy after spontaneous rupture of renal angiomyolipoma

Role of peripheral blood mononuclear cell transportation from mother to baby in HBV intrauterine infection